You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Claims for Patent: 8,012,472

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,012,472

Title:	Compositions and methods for suppressing fibrocytes
Abstract:	The present invention relates to the ability of anti-Fc.gamma.R antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.
Inventor(s):	Gomer; Richard (Houston, TX), Pilling; Darrell (Pearland, TX)
Assignee:	William Marsh Rice University (Houston, TX)
Application Number:	11/535,649
Patent Claims:	1. A method of suppressing fibrocyte formation in a subject in need thereof comprising administering to the subject having pulmonary fibrosis an anti-Fc.gamma.R antibody in an amount sufficient to suppress fibrocyte formation in a lung. 2. The method of claim 1, wherein the anti-Fc.gamma.R antibody is administered at a concentration of at least 1.0 .mu.g/ml. 3. The method of claim 1, wherein the anti-Fc.gamma.R antibody is administered at a concentration of at least 0.1 .mu.g/ml. 4. The method of claim 1, wherein the antibody is an IgG. 5. The method of claim 1, wherein the antibody is an anti-Fc.gamma.RI antibody. 6. The method of claim 1, wherein the antibody is an anti-Fc.gamma.RII antibody. 7. The method of any one of claims 4-6, wherein the antibody comprises an F(ab').sub.2 fragment. 8. The method of any one of claims 4-6, wherein the antibody comprises an Fc fragment. 9. The method according to claim 1, wherein the pulmonary fibrosis comprises a condition selected from the group consisting of: Adalimumab-associated pulmonary interstitial fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, diffuse alveolar damage disease, pulmonary hypertension, neonatal bronchopulmonary dysplasia, and emphysema. 10. The method of claim 1, wherein the antibody is an anti-Fc.gamma.RIII antibody.

Details for Patent 8,012,472

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2022-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2022-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2022-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014	⤷ Try a Trial	2022-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015	⤷ Try a Trial	2022-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016	⤷ Try a Trial	2022-12-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.